NewslettersHuman Immunology NewsNivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair Proficient Colorectal CancerBy Jamie Kang - May 27, 20250113Researchers investigated whether LAG-3/PD-1 inhibition would improve clinical outcomes in a mismatch repair proficient colorectal cancer subset.[Clinical Cancer Research]Abstract